Under the agreement, AbCelex has an exclusive license to develop and commercialize NRC-IBS’s Pentabody platform for all in vitro clinical diagnostic applications.

NRC-IBS will receive an up-front payment and milestone payments in addition to royalties on future product sales.

AbCelex Technologies is a Canadian biotechnology company focused on creating new products for diagnosis of a diverse set of disease-associated biomolecules.